Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132161 | 1.00 | AMY1A (0.38) | AMY1ANFE2L2PKMRELAALDH1A1 | |
| SCHEMBL22097420 | 0.82 | NFE2L2 (0.36) | AMY1ANFE2L2PKMNPC1MAPT | |
| SCHEMBL4031066 | 0.77 | NFE2L2 (0.36) | AMY1ANFE2L2PKMRELAALDH1A1 | |
| SCHEMBL16958007 | 0.77 | NFE2L2 (0.41) | AMY1ANFE2L2PKMRELAALDH1A1 | |
| SCHEMBL42391 | 0.77 | ERN1 (0.42) | AMY1ANFE2L2PKMRELAALDH1A1 | |
| SCHEMBL29442889 | 0.76 | NFE2L2 (0.54) | NFE2L2ALDH1A1CES2CES1CA3 | |
| SCHEMBL2787330 | 0.76 | HSP90AA1 (0.41) | ALDH1A1LMNACA9 | |
| SCHEMBL491580 | 0.76 | NFE2L2 (0.54) | NFE2L2ALDH1A1CES2CES1CA3 | |
| SCHEMBL29661857 | 0.76 | HSP90AA1 (0.41) | ALDH1A1LMNACA9 | |
| SCHEMBL25287952 | 0.74 | NFE2L2 (0.38) | NFE2L2ALDH1A1LMNATGM2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4368618-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-3107918-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9382279-B2 | Copper catalyzed halogenaton and reaction products | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382279-B2 | Copper catalyzed halogenaton and reaction products | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| CN-101273036-A | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | CN | disclosed |
| EP-1931660-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | MALT1, CYP51A1, BCR | AMY1A 24/4885NFE2L2 2173/4885PKM 3614/4885 |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | GPR119, CPT1A, PC | AMY1A 935/4885NFE2L2 2036/4885PKM 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.